Industry news that matters to you.  Learn more

Affymetrix Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests

Affymetrix, Inc. (NASDAQ:AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

Abcodia and BIOUNIVERSA Announce Collaboration on BAG3 Biomarker for the Early Detection of Pancreatic Cancer

Abcodia, a biomarker validation company, has today announced a collaboration with BIOUNIVERSA Srl, a spin off from the University of Salerno, which aims to advance the development of the BAG3 protein biomarker for use in the early detection of pancreatic cancer.

Proteome Sciences Completes 1,000-Patient Study of Alzheimer’s Plasma Biomarkers

Proteome Sciences, in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, recently announced the completion of a large 1,000-patient sample Alzheimer’s Disease (AD) biomarker validation study. Preliminary results from the study suggest that the biomarker panels identified have potential diagnostic and prognostic utility that could form the basis of a series of simple blood tests for the diagnosis and management of AD.

Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay

Berg Diagnostics, a Boston-based molecular diagnostics company has received Massachusetts Clinical Laboratory Licensure and Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA).

Abcodia and VolitionRX Collaboration Advances the Discovery of Blood-based Biomarkers for Cancer

Abcodia, a biomarker validation company, has today announced a collaboration with life sciences company VolitionRx which will advance the development of biomarkers for the early detection of cancer.